Top Markets
Coin of the day
Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTE
Rank in Stocks #5459
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise... Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Share Price
$93.80
Last synced: 2025-04-28
Market Cap
$2.68B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Aerovate Therapeutics, Inc. (AVTE)

Category

EPS for Aerovate Therapeutics, Inc. (AVTE)
EPS as of June 2026 TTM: $-3.65K
According to Aerovate Therapeutics, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-3.65K. At the end of 2023 the company had a EPS of $-2.87 an increase over its 2022 EPS that were of $-2.10.
EPS history for Aerovate Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-3.65K 149,412.70%
2024 $-2.44 -14.98%
2023 $-2.87 36.67%
2022 $-2.10 12.30%
2021 $-1.87 -95.34%
2020 $-40.17 28,592.86%
2019 $-0.14 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -100.47%
US
$27.74 -100.76%
NL
$-7.98 -99.78%
US
$-5.29 -99.85%
AU
- -
CH